{"type":"trials","record":{"id":29258,"source_id":"clinicaltrials-gov","external_id":"NCT06386380","title":"Adversity and Its Association With the Development and Expression of Rheumatic Diseases","brief_summary":"Epidemiological evidence shows that adverse experiences, particularly, but not exclusively in childhood, are predictors of poor long-term health outcomes and certain social domains. In the field of rheumatic diseases, traumatic events, not only in childhood, have been associated with hospitalization, chronic pain, inflammation, worse outcomes, severity of the disease, and mortality. Some mechanisms proposed to explain the association between the experience of adversity and the development of chronic diseases include an impact on the physiology of immune system cells, gene expression due to DNA modification, and cellular senescence. With this background, the investigators wonder if, for patients with rheumatoid arthritis, the presence of adversity understood as a history of violence in childhood and abuse due to suffering from rheumatoid arthritis is associated with markers of cellular senescence and with the severity of illness.","overall_status":"Unknown","phases":[],"study_type":"OBSERVATIONAL","sponsor":"National Institute of Medical Sciences and Nutrition, Salvador Zubiran","enrollment":110,"countries":[],"start_date":"2024-06-01","completion_date":"2026-02-01","last_update_date":"2024-05-03","source_url":"https://clinicaltrials.gov/study/NCT06386380","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:16:08.862442+00:00","last_seen_at":"2026-09-25T06:05:20.497+00:00","metadata":{"sex":"ALL","acronym":"RD","age_range":"18 Years to 100 Years","comparator":null,"organization":"National Institute of Medical Sciences and Nutrition, Salvador Zubiran","interventions":["Rheumatic diseases Mistreatment Scale (RDMS)","Routine assessment of patient index data 3 (RAPID-3)","Health Assessment Questionnaire (HAQ)","WHOQOL-BREF","Depression, Anxiety and Stress Scale (DASS-21)","Brief Resilient Coping Scale","Expression of CDKN2A /p16INK4a","Immunophenotype of leukocyte subpopulations","Telomere length","Cellular senescence"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Adversity and senescence in patients with rheumatoid arthritis — At inclusion (baseline moment) (cross-sectional study)]","Eexpression of the p16INK4a gene in CD3+ — At inclusion (baseline moment) (cross-sectional study)]","Telomere length — At inclusion (baseline moment) (cross-sectional study)]"],"design_description":null,"source_has_results":false},"controlled_terms":["RhA - Rheumatoid Arthritis","Rheumatic diseases Mistreatment Scale (RDMS)","Routine assessment of patient index data 3 (RAPID-3)","Health Assessment Questionnaire (HAQ)","WHOQOL-BREF","Depression, Anxiety and Stress Scale (DASS-21)","Brief Resilient Coping Scale","Expression of CDKN2A /p16INK4a","Immunophenotype of leukocyte subpopulations","Telomere length","Cellular senescence"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: cellular senescence.","quality_checked_at":"2026-09-25T06:05:21.960425+00:00","duplicate_cluster_key":"id:nct06386380","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2024-06-01 to 2026-02-01","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years to 100 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:05:20.510Z","intervention":["Rheumatic diseases Mistreatment Scale (RDMS)","Routine assessment of patient index data 3 (RAPID-3)","Health Assessment Questionnaire (HAQ)","WHOQOL-BREF","Depression, Anxiety and Stress Scale (DASS-21)","Brief Resilient Coping Scale","Expression of CDKN2A /p16INK4a","Immunophenotype of leukocyte subpopulations","Telomere length","Cellular senescence"],"participants":110,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Adversity and senescence in patients with rheumatoid arthritis — At inclusion (baseline moment) (cross-sectional study)]","Eexpression of the p16INK4a gene in CD3+ — At inclusion (baseline moment) (cross-sectional study)]","Telomere length — At inclusion (baseline moment) (cross-sectional study)]"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"senolytics","is_published":true,"match_reasons":["Abstract contains controlled term: cellular senescence.","Source terminology contains: cellular senescence.","Abstract supplies longevity context: senescence.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Senolytics","slug":"senolytics"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/29258","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}